Angiogenix

Angiogenix has invented a therapeutic mixture, including a combination of L-arginine and nitric oxide synthase agonists (i.e., nitroglycerin), for the treatment of diseases related to vasoconstriction, demonstrating better efficacy in reducing clinical endpoints and mortality.